Persistence of bDMARD therapy in Rheumatoid Arthritis after first-line TNF-inhibitor failure: the RECORD study of the Italian Society for Rheumatology.
Greta CarraraLisa ArgnaniAnna ZanettiA ZabottiAlen ZabottiGian Domenico SebastianiMarco SebastianiAnd Carlo Alberto ScirèPublished in: Scandinavian journal of rheumatology (2022)
Among RA patients failing a first TNFi, switching is associated with marginally better persistence, in particular for ABA and RTX, with only marginal differences in patients on concurrent csDMARDs.
Keyphrases
- rheumatoid arthritis
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- peritoneal dialysis
- prognostic factors
- radiation therapy
- squamous cell carcinoma
- disease activity
- stem cells
- ankylosing spondylitis
- systemic lupus erythematosus
- systemic sclerosis
- patient reported
- idiopathic pulmonary fibrosis